Today: 21 May 2026
Browse Category

NASDAQ:FRGT 28 October 2025 - 20 November 2025

Freight Technologies (FRGT) Seals Fetch AI Deal and $1M Financing as Zayren Launch Supercharges Volatile Rally

Freight Technologies (FRGT) Seals Fetch AI Deal and $1M Financing as Zayren Launch Supercharges Volatile Rally

Freight Technologies announced a multi-year AI services deal with Fetch Compute and launched its new Zayren platform, triggering FRGT shares to surge over 70% intraday Wednesday. The company issued $1 million in convertible notes and canceled a prior $5.2 million FET token agreement, including returning 11.3 million tokens. Fetch will receive equity and usage credits as part of the new AI partnership.
20 November 2025
···
Freight Technologies (FRGT) Soars on Nov. 19 After Launching ‘Zayren’ AI Freight Pricing & Carrier-Matching Platform

Freight Technologies (FRGT) Soars on Nov. 19 After Launching ‘Zayren’ AI Freight Pricing & Carrier-Matching Platform

Freight Technologies shares surged as much as 74% intraday Wednesday after the company launched Zayren, an AI-powered freight rate and carrier-matching platform for U.S.–Mexico trucking. Trading volumes spiked as FRGT stock hit between $1.01 and $1.14, according to multiple data providers. The company said it plans further AI features for Zayren in 2026.
19 November 2025
··
Freight Technologies (NASDAQ: FRGT) Stock Skyrockets on AI Upgrades and Key Deals – Is the Rally Just Beginning?

Freight Technologies (NASDAQ: FRGT) Stock Skyrockets on AI Upgrades and Key Deals – Is the Rally Just Beginning?

FRGT shares jumped about 57% at the Oct. 28 open after closing at $1.23 the previous day, following new product launches including expanded GPS integration and an AI invoice module. The stock remains down roughly 84% year-over-year. CEO Javier Selgas highlighted recent tech upgrades and new partnerships. Analysts cite ongoing sector weakness and forecast continued volatility for FRGT.
28 October 2025
··

Stock Market Today

  • Hidden Dividend Stars: 3 SGX Stocks with Growing Payouts and Zero Debt
    May 21, 2026, 12:41 AM EDT. Three Singapore Exchange (SGX) listed companies-HRnetGroup, Credit Bureau Asia, and an unnamed third-offer rising dividends supported by zero debt and strong cash reserves. HRnetGroup posted a 15% profit increase and 5% dividend rise for FY2025, underpinned by S$262.9 million cash and zero debt. Credit Bureau Asia raised dividends despite a slight profit dip, backed by S$71.1 million in liquid assets and a debt-free balance sheet. These firms illustrate how clean balance sheets combined with rising dividends provide more reliable income than yield alone, especially during economic uncertainty.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop